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Early diagnosis of nerve damage in leprosy is quite important for preventing the deformities. With an aim to 
find a good marker we have investigated Krox-20 as early peripheral nerve damage indicator in leprosy. 
Ambulatory patients of Kediri Leprosy Hospital, Malang, Indonesia have been studied. Degree of disability 
was measured based on WHO's criteria. Immunohistochemistry was used to study the expression of Krox-20 
on Schwann cells on nerve twigs in skin biopsies from leprosy cases. Receiver Operating Characteristic (ROC) 
curve was used to determine cut off value. Of all 79 leprosy patients studied, 36 patiens had degree of 
disability 0, and 43 patients had degree of disability 1. Analysis of ROC curve shown that cut off value for Krox-
20, was 8 and the cases in whom degree of disability was 0 (zero) had significantly higher mean values than 
those with degree of disability 1 (mean: 12.56 vs 4.24 (p<0.05)). Krox-20 appears to be a potentially good 
biomarker  to identify early peripheral nerve damage in leprosy.
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Introduction
Leprosy, a chronic infectious disease caused
by Mycobacterium leprae, is known to have 
predilection for sites like skin and peripheral 
nerves, especially Schwann cells (Barker 2006, 
Scollard 2008, Bhat and Prakash 2012). Large 
number of people in different countries of the  
world have suffered from disabilities caused by 
leprosy in the past, many continue to have 
deformities even now (Gitte et al 2015, Goncalves 
et al 2009, Nardi et al 2012, Noor et al 2010,
Ramos et al 2011 & 2012, van Brakel et al 2008). 
Current treatment for leprosy mainly focuses on 
inhibition/ killing of M. leprae but has only partial 
role directly in influencing the recovery the 
damaged peripheral nerves (Goncalves et al 
2009). Early detection of nerve damage is a 
challenge and is considered to be very important 
(Harboe et al 2005, Walker and Lockwood 2006). 
Several studies about early detection of damaged 
nerves by M. leprae invasion had been done,  
these studies have employed  different tools and 
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techniques such as the usage of ultrasound (USG) 
to detect the damaged peripheral nerves (Jain
et al 2009), vasomotor reflexes and sympathetic 
skin response (Wilder-Smith 1998), the exami-
nation of the electrophysiology of the involving 
nerves (Kar et al 2013), the examination of axonal 
signs on the skin lesions (Michelin et al 2012) and 
myelin protein based immunological assays 
(Singh et al 2015). 
According to WHO, there are 3 stages of leprosy 
disabilities, from asymptomatic to full blown 
disabilities (WHO 1970). WHO (1988) grading is 
different. In general, Saddon classified peripheral 
nerve damage into 3 stages: neuropraxia, 
axonotmesis, and neurotmesis; while in leprosy 
case, the nerves are damaged by demyelination 
of peripheral nerves (Barker 2006, Bhat and 
Prakash 2012).
Schwann cells have an important function to 
synthesize and maintain the myelin sheath. If 
these cells are infected, then demyelination will 
occur as a result of neuritis. It has been observed 
that infection of Schwann cells by M. leprae 
results in the demyelination of nerves in leprosy 
patients (Scollard 2008). The presence of 
Schwann cells infection by M. leprae will cause 
Schwann cells dysfunction, including decrease
in neurotropic substances and also myelin 
synthesis; which may lead to demyelination. 
Relationship between triggering of certain 
signaling mechanism and demyelination has
been reported by Rambukkana et al (2006).
Krox20 or Early Growth Response 2 (Egr 2) is a 
transactivator needed for the myelination 
proccess of Schwann cells. It is a gene that encode 
the formation of myelin sheath in Schwann cells 
(Ghislain and Charnay 2006, LeBlanc et al 2007). 
The other function of Krox20 is to regulate myelin 
genes like MPZ, PMP22, Connexin-32, and MAG 
(myelin associated glycoprotein) (LeBlanc et al 
2007). One of the many strategies to detect early 
peripheral nerve damage would be studying the  
alterations in various markers associated with 
myelination or demyelination such as NRG1 
(Fricker and Bennett 2011, Liu et al 2011), Krox-20 
(Decker et al 2006, Ghislain and Charny 2006, 
Murphy et al 1996, Parkinson et al 2004), P0 
(D'urso et al 1999, Suneetha et al 2003, LeBlanc
et al 2007), and PMP22 (D'urso et al 1999, Jones
et al 2011). Among these Krox-20 is an attractive 
target because of its role in myelin maintenance 
(Decker et al 2006). While leprosy can be 
diagnosed easily and it does not require advanced 
technology, early detection of nerve damage
is a challenge. The purpose of this study is to 
determine the usefulness of expression of Krox-
20 as a marker of early nerve damage in leprosy 
patients.
Materials and Methods
All leprosy patients who came to the outpatient 
clinic in RS Kusta Kediri during August 2014 until 
December 2014 and who fulfilled the inclusion 
criteria were included in the study. Criteria
for inclusion was - multibacillary (MB) types of 
leprosy patients with degree of disability 0 and 1, 
age 14 until 50 years old, and who agred to sign 
the informed consent of this study. The exclusion 
criteria were - leprosy patients who were quite 
sick, had received oral glucocorticoid during the 
last 7 days, had history of tuberculosis and/or 
diabetes mellitus, and history of head trauma and 
any peripheral nerve lesion.
This study evaluated the Krox20 expression on 
Schwann cells in the skin biopsy of leprosy 
patients. Krox-20 expression was determined
by counting the cells that express Krox-20, 
characterized by its brown color (exceed the 
control's color), using light microscope Olympus®  
(Antunes et al 2003, 2006, check/Cite reference). 
the samples were chosen using consecutive 
sampling methods. Diagnosis of leprosy was 
made using the WHO criteria (WHO 1988) based 
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on original Ridley and Jopling Classification 
(Ridley and Jopling 1966). Degree of disability 
wasalso determined using the WHO criteria 
(WHO 1970). The number of  cells showing Krox 
20 expressionwerecompared between two 
groups by using student T-test. The cut-off point 
of Krox-20 expression was determined using 
Receiver Operating Characteristic (ROC) analysis.
Results
This study was conducted on 79 MB leprosy 
patients: 36 patients with type 0 degree and
43 patients with type 1 degree of disability. The 
basic characteristics of the study subjectsare 
summarized in Table 1.
This study evaluated the Krox20 expression on 
Schwann cells in the skin biopsy of leprosy 
patients and it was observed that there was a 
significant difference of Krox20 expression 
between patients with degree of disability 0 and 
1. (T-tailed test shows F=8.881 with p=0.000 
(p<0.05)).
Findings summarized in Fig. 1 show a significant 
decline in Krox-20 expression in degree of 
disability 1 compared to degree of disability
0 (T-test, F=8.881, p=0.000 (<0.005)).
Table 2 shows that with cut off value 8 the 
sensitivity and specificity can be 100%. It means 
that if the Krox20 expression is more than 8,
Table 1 : Age and gender distribution in leprosy patients with degree of disability 0 and 1
Age group Degree 0 Total (%) Degree 1 Total (%)
Male(%) Female(%) Male(%) Female (%)
14 - 25 4(66) 2(33) 6(17) 3(43) 4(57) 7(16)
26 - 35 7(54) 6(46) 13(36) 5(38) 8(62) 13(30)
36 - 45 6(50) 6(50) 12(33) 8(47) 9(53) 17(40)
46 - 55 3(60) 2(40) 5(14) 3(50) 3(50) 6(14)
Total 20(56) 16(44) 36(100) 19(44) 24(56) 43(100)
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Fig. 1 :  The histogram of Krox20 distribution
on Schwann cells
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Fig 2 : ROC (Receiver Operating Characteristic)
curve of Krox-20.
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the degree of disability will be  0, and vice versa. 
From the ROC curve below (Figure 2), the area 
under the curve is 1.0 (100%) with p=0.000.
From the picture above (Fig. 3), it can be seen that 
in panel A (degree of disability 0), there were still 
many Krox2 - expression (red arrow) among the 
Schwann cells (back arrow). On the other hand in 
patients with degree of disability 1, it can be seen 
that the expression of Krox 20 was minimal (red 
arrow).
Discussion
In this study, the sample population was 36 MB 
leprosy patients with degree of disability 0 and 43 
patients with degree of disability 1. This sample  
size was chosen because the purpose of study
was to detect the presence of peripheral nerve 
damage in patients with degree of disability 1. 
Most patients with disability grade 0 were in the  
age group of 26-35 years old (13 patients, 36%), 
while a major proportion with disability grade 1 
was in the  age group 36-45 year old (17 patients, 
40%). A large study in Ethiopia with total 839 
patients showed that most leprosy patients were 
more than 35 years old (Ramos et al 2012). This 
indicated that many leprosy patients are in 
productive age in which disabilities become an 
important problem from economic point of view.
Our study included only disability grade 0 and 1, 
since goal is to find a diagnostic marker for 
detection of early nerve damage. In the 
outpatient clinic of RS Kusta Kediri, there were 
43.54% patients (from total 79 leprosy patients) 
who had disability grade 1; the rest had disability 
grade 0, thus the groups were largely comparable 
by names, age and gender, however, there were 
Fig 3 : The expression of Krox20 on Schwann cells
Table 2 : Krox20 expression on Schwann cells 
KEL N Mean SD
Degree of disability 0 36 12.56 2.39
43 4.24 1.34
Degree of disability 1
F 8.88
P 0.00
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some differences. Clearly patients with disability 
grade 0 in this study significantly expressed more 
Krox-20 than patients with disability grade 1.
This study used immunohistochemistry approach 
to identify the proteins through Ag-Ab binding 
using light microscope. The limitation of this 
study are that it cannot describe the whole 
proccess and cannot prove the causal relationship 
because of the study methods. Though there is 
disadvantage of being an invasive approach in 
which biopsy is necessary, ithas the advantage of 
being feasible in the same specimen used for 
diagnosis and classification. This techniques 
needs to be  compared with other approaches 
tried earlier or being used currently (Antunes et al 
2003 and 2006, Jain et al 2009, Kar et al 2013, 
Michelin et al 2012, Singh et al 2015, van Brakel et 
al 2008) for detection and or quantify nerve 
damage in leprosy. Such comparison should be  
on significant numbers using proper sampling 
procedure which is the limitation of our study.
To conclude the present study shows that Krox-20 
expression on Schwann cells in skin biopsy 
specimens is a good useful diagnostic tool to 
detect early disability in leprosy patients with cut-
off value 8 cells/high power field. Further studies 
are needed to evaluate the role of Krox-20 in PB 
types of leprosy patients.
References
1. Antunes SLG, Chimelli LM, Rabello ET et al ( 2006). 
An immunohistochemical, clinical and electro-
neuromyographic correlative study of the neural 
markers in the neuritic form of leprosy. Braz  J Med 
Biol Res. 39 : 1071-1081.
2. Antunes SLG, Liang Y, Neri JA et al (2003). The 
expression of NGFr and PGP 9.5 in leprosy 
reactional cutaneous lesions: an assessment of 
the nerve fiber status using immunostaining. Arq 
Neuropsiquiatr. 61: 346-52.
3. Barker LP (2006). Mycobacterium leprae inter-
actions with the host cell: recent advances. 
Review Article. Indian J Med Res. 123: 748-759.
4. Bhat RM and Prakash C (2012). Leprosy: an 
overview of Pathophysiology. Interdiscip Perspect 
Infect Dis. 2012: 181089. doi: 10.1155/2012/ 
181089. Epub 2012 Sep 4.
5. Decker L, Desmarquet-Trin-Dinh C, Taillebourg E
et al (2006). Peripheral Myelin Maintenance
Is a Dynamic Process Requiring Constant Krox20 
Expression. J  Neurosc. 26: 9771-9779.
6. D'urso D, Ernhardt P, Muller HW (1999). Peripheral 
Myelin Protein 22 and Protein Zero: a Novel 
Association in Peripheral Nervous System Myelin.
J Neurosc. 19: 3396-3403.
7. Fricker FR, Bennett DLH (2011). The role of 
neuregulin-1 in the response to nerve injury. 
Future Neurol. 6 : 809-822.
8. Ghislain J, Charnay P (2006). Control of myeli-
nation in Schwann cells: a Krox20 cis-regulatory 
element integrates Oct 6, Brn2 and Sox10 
activities. EMBO reports. 7: 52-58.
9. Gitte SV, Sabat RN, Kamble KM (2016). Childhood 
leprosy in an endemic area of Central India. Indian 
Pediatr. 53: 221-4. (suggested for inclusion).
10. Goncalves SD, Sampaio RF, Antunes CMF (2009). 
Predictive factors of disability in patients with 
leprosy. Rev Saude Publica, 43: 267-74.
11. Harboe M, Abraham A, Leekassa R (2005). 
Challenges presented by nerve damage in leprosy. 
Lepr Rev. 76: 5-13.
12. Jain S, Visser LH, Praveen TLN et al (2009). High-
Resolution Sonography: A New Technique to 
Detect Nerve Damage in Leprosy. PLoS Negl Trop 
Dis. 3(8): e498.
13. Jones EA, Camila LA, Rajini S et al (2011). 
Regulation of the PMP22 gene through an intronic 
enhancer. J Neurosci. 31: 4242-4250.
14. Kar S, Krishnan A, Singh N et al (2013). Nerve 
damage in leprosy: an electrophysiological 
evaluation of ulnar and median nerves in patients 
with clinical neural deficits: a pilot study. Indian 
Dermatol Online J. 4: 97-101.
15. Liu X, Ryan B, Dong-Min Y et al (2011). Specific 
Regulation of NRG1 Isoform Expression by 
Neuronal Activity. J Neurosc. 31: 8491-8501.
Widasmara et al110
16. LeBlanc SE, Rebecca MW et al (2007). Neuropathy-
Associated Egr2 Mutants Disrupt Cooperative 
Activation of Myelin Protein Zero by Egr2 and 
Sox10. Mol Cell  Biol. 9: 3521-3529.
17. Murphy P, Topilko P, Schneider-Maunoury S
et al (1996). The Regulation of Krox-20 expression 
reveals important steps in the control of peri-
pheral glial cell development. Development. 122: 
2847-2875.
18. Nardi SMT, Paschoal Vdel A, Chiaravalloti-Neto F
et al (2012). Leprosy-related disabilities after 
release from multidrug treatment: prevalence and 
spatial distribution. Rev Saúde Pública. 46: 969-77 
www.scielo.br/rsp.
19. Noor SM, Zafar A, Azhar R et al (2010). Frequency 
of Disabilities in Newly Diagnosed Patients of 
Leprosy Presenting to Lady Reading Hospital 
Peshawar. Ann Pak Inst Med Sci. 6: 210-213.
20. Parkinson DB, Bhaskaran A, Droggiti A et al (2004). 
Krox-20 inhibits Jun-NH-terminal kinase/c-Jun to 
control Schwann cell proliferation and death. J Cell 
Biol. 164: 385-394.
21. Rambukkana A, Tapinos N, Ohnishi M (2006). 
ErbB2 receptor tyrosine kinase signaling mediates 
early demyelination induced by leprosy bacilli. Nat 
Med. 12 : 961-966.
22. Ramos JM, Reyes F, Lemma D et al (2011). 
Disability profile in leprosy patients' diagnoses in a 
rural leprosy centre in Ethiopia during 1999 - 2009. 
Trop Doct. 41: 51-3.
23. Ramos JM, Martínez-Martín M, Reyes F et al 
(2012). Gender differential on characteristics and 
outcome of leprosy patients admitted to a long-
term care rural hospital in South-Eastern Ethiopia. 
Ramos et al. Int J Equity in Health, 11: 56.
24. Ridley DS, Jopling WH (1966). Classification of 
leprosy according to immunity. A five-group 
system. Int J Lepr Other Mycobact Dis. 34:  255-
273.
25. Scollard DM (2008). The biology of nerve injury in 
leprosy. Lepr Rev. 79 : 242-253.
26. Singh I, Yadav AR, Mohanty KK et al (2015). 
Molecular mimicry between Mycobacterium 
leprae proteins (50S ribosomal protein L2 and 
Lysyl-tRNA synthetase) and myelin basic protein:
a possible mechanism of nerve damage in leprosy. 
Microbes Infect. 17: 247-57.
27. Suneetha LM, David S, Juan JA et al (2003). 
Mycobacterium leprae Binds to a Major Human 
Peripheral Nerve Glycoprotein Myelin P Zero (P ). 0
Neurochem Research. 28 : 1393-1399.
28. Syed N, Reddy K, Yang DP et al (2010). Soluble 
neuregulin-1 has bifunctional, concentration-
dependent effects on Schwann cell myelination.
J Neurosci. 30 : 6122-31.
29. van Brakel WH, Peter GN, Einar PW et al (2008). 
Early Diagnosis of Neuropathy in Leprosy - 
Comparing Diagnostic Tests in a Large Prospective 
Study (the INFIR Cohort Study). PLoS Negl Trop Dis. 
2(4): e212.
30. Walker SL, Lockwood DNJ (2006). The clinical and 
immunological features of Leprosy. Brit Med Bull. 
77 and 78: 103-121.
31. Wilder-Smith A (1998). Autonomic Neuropathy in 
Leprosy. Neurol J South East Asia. 3: 15-17.
32. WHO Technical Report Series ( 1970). 459 : 26-30.
th33. WHO Expert Committee on Leprosy, 6  Report 
(1988). Technical Report Series No. 768.
How to cite this article :  (2016). 
Marker Krox-20 for Detection of Early Disability in Leprosy.  88 : 105-110.
Widasmara D, Agusni I and Turchan A Evaluation of Myelin Sheath 
Indian J Lepr.
